Press Release

Cyxone appoints Carl-Magnus Högerkorp as permanent CEO

December 13, 2022 13:10 (CET)

Cyxone (publ), a biotech company in autoimmune diseases, has appointed Carl-Magnus Högerkorp as permanent CEO. Carl-Magnus Högerkorp has had the role of acting CEO since June 20, 2022.

In Cyxone's continued work to strengthen and develop the company, the board decided to appoint Carl-Magnus as permanent CEO. Carl-Magnus has been an important part of the company since he started as the COO and has been a driving factor in the value-creating of the projects. Before Carl-Magnus started at Cyxone in 2021, he held several leading roles in various biotech companies in Lund. He worked as the CSO at Xintela focusing on regenerative medicine and oncology. After this, Carl-Magnus assumed the role of CEO of the start-up company Edvince AB and their stroke drug in the clinical phase. The most recent experience is from his time as CEO at Canimguide Therapeutics AB, which develops a concept in immuno-oncology in the clinical phase. In 2021, Carl-Magnus was CEO of ImModulate Pharma AB, which he also co-founded.

“The board is pleased that Carl-Magnus Högerkorp has accepted to become permanent CEO of Cyxone. The strategic collaboration, which is the most important task of the CEO and the board, has been strengthened in recent months and developed towards creating new business.” comments Bert Junno the chairman of the board at Cyxone.

“I am very happy to have received the trust to continue working with Cyxone in this role. Cyxone and their exciting projects in immunomodulation have interested me since a few years back. It is of course therefore a joy to now be able to participate and continue to develop these projects, look ahead, and capture the incredible intrinsic opportunities.” says Carl-Magnus Högerkorp, CEO, Cyxone.

Bert Junno, Chairman of the Board
Tel: +46 707 77 22 09

About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit

Open Press release